Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer Clinical Trial
Official title:
Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer
This study is being offered to patients who are post-menopausal, have breast cancer with a
positive estrogen and/or progesterone hormone receptor test and are currently awaiting
surgery for breast cancer.
The purpose of this study is to determine whether abiraterone acetate has different hormonal
and genomic effects than non-steroidal aromatase inhibitors in the treatment of
post-menopausal hormonal receptor positive primary operable breast cancer
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science